Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06961630
EARLY_PHASE1

Post-Operative Biomarker-Guided Precision Medicine For Cardiovascular Risk Reduction

Sponsor: NYU Langone Health

View on ClinicalTrials.gov

Summary

The goal of this pilot study is to assess enrollment feasibility of a randomized trial of direct oral anticoagulant and high-intensity statin therapy versus usual care in patients with Myocardial Injury after Noncardiac Surgery (MINS). The primary aims of this study are to assess feasibility, study drug adherence, and optimize study design (entry criteria, study endpoints, sample size calculation, site selection) and recruitment strategies for the future multicenter randomized clinical trial studying biomarker-based care in post-operative patients at elevated cardiovascular (CV) risk.

Official title: A Pilot Randomized Trial of Post-Operative Biomarker-Guided Precision Medicine With Rivaroxaban and Atorvastatin for Cardiovascular Risk-Reduction

Key Details

Gender

All

Age Range

45 Years - Any

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2025-10-07

Completion Date

2027-03-31

Last Updated

2026-04-06

Healthy Volunteers

No

Interventions

DRUG

Rivaroxaban

Rivaroxaban 2.5mg will be orally administered twice daily for 6 months.

DRUG

Atorvastatin

Atorvastatin 80mg will be orally administered daily for 6 months.

Locations (1)

NYU Langone Health

New York, New York, United States